Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.20    -0.40 (-0.30%)
Bid:
130.80
Ask:
131.20
Spread: 0.40 (0.306%)
Market Cap: £319.36m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
27th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Nov 202012:00 pmRNSVedanta Appoints Karuna CFO Troy Ignelzi to BOD
23rd Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th Nov 20207:00 amRNSPRTC LYT-100 Shows PK & Tolerability Ph1 POC
16th Nov 20207:00 amRNSPureTech to Present at Three Investor Conferences
13th Nov 20205:05 pmRNSGuidance for Exchanging Ordinary Shares into ADSs
13th Nov 20205:00 pmRNSDirector/PDMR Shareholding
13th Nov 20201:04 pmRNSGelesis Presents New Data at The Liver Meeting
13th Nov 20207:00 amRNSPureTech to Commence Nasdaq Trading on 16 November
12th Nov 20202:04 pmRNSSonde Respiratory Portal Available to Developers
11th Nov 20201:03 pmRNSVor Licenses Clinical-Stage CD33 CAR-T Therapy
5th Nov 20207:00 amRNSPureTech Presents at Credit Suisse Conference
3rd Nov 20205:10 pmRNSGelesis Presents New Data at ObesityWeek
2nd Nov 20204:35 pmRNSDirector/PDMR Shareholding
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing
21st Oct 20201:03 pmRNSAkili Presents New Data on EndeavorRx at AACAP
20th Oct 20201:08 pmRNSVor Appoints Biotech Leader Matt Patterson to BOD
12th Oct 20201:00 pmRNSNew Vedanta VE202 Data Presented at UEG Week
7th Oct 20201:03 pmRNSAkili Adds Award-Winning Marketing Leader as CMO
5th Oct 202012:00 pmRNSAlivio Awarded $3.3M from DoD to Advance ALV-304
1st Oct 20207:05 amRNSPureTech Appoints Biocon Founder Kiran Shaw to BOD
1st Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20202:00 pmRNSBARDA Awards Vedanta Up to $76.9M to Advance VE303
29th Sep 202012:00 pmRNSAlivio Adds Dr Harry Leider to Board of Directors
25th Sep 20204:35 pmRNSPrice Monitoring Extension
23rd Sep 20207:00 amRNSPureTech Nasdaq Listing Progresses
18th Sep 20204:41 pmRNSSecond Price Monitoring Extn
18th Sep 20204:35 pmRNSPrice Monitoring Extension
18th Sep 202010:15 amRNSPrice Monitoring Extension
16th Sep 20201:00 pmRNSVedanta Appoints Drug Development Leader as CMO
4th Sep 202012:42 pmRNSGelesis Presents Plenity Efficacy and Safety Data
4th Sep 202012:07 pmRNSSecond Price Monitoring Extn
4th Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20204:40 pmRNSSecond Price Monitoring Extn
28th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Aug 20207:00 amRNSHalf-year Report
26th Aug 20201:02 pmRNSVor Appoints John King as Chief Commercial Officer
26th Aug 202012:40 pmRNSPRTC Receives $100M from Founded Entity Shares
26th Aug 202012:08 pmRNSPublication of Shareholder Circular
25th Aug 20202:05 pmRNSSonde Makes Acquisition in Vocal Biomarker Space
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20207:00 amRNSPureTech to Present at Wedbush PacGrow Conference
3rd Aug 20207:00 amRNSTotal Voting Rights
30th Jul 20201:02 pmRNSVor Appoints Life Science Leader to BOD
30th Jul 202012:07 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 202012:08 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.